Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : PINOTBIO
Deal Size : Undisclosed
Deal Type : Financing
LOTTE BIOLOGICS Announces Investment in PINOT BIO, ADC Platform Development Pioneer
Details : The investment will facilitate the creation of a cross-industry synergistic environment for the development and production of ADC platforms including, PINOT-ADC™, a next-generation ADC anti-cancer drug platform developing PBX-001 (sacituzumab), targeti...
Brand Name : PBX-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 21, 2023
Lead Product(s) : Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : PINOTBIO
Deal Size : Undisclosed
Deal Type : Financing
LOOKING FOR A SUPPLIER?